Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Shares of Innovus Pharmaceuticals (OTCMKTS INNV) remained flat at $$0.10 during trading on Thursday. 840,154 shares of the stock traded hands, compared to its average volume of 1,038,591. Innovus Pharmaceuticals has a twelve month low of $0.08 and a twelve month high of $0.39.

Innovus Pharmaceuticals (OTCMKTS:INNV) last announced its earnings results on Tuesday, November 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $2.22 million during the quarter. Innovus Pharmaceuticals had a negative net margin of 102.95% and a negative return on equity of 330.39%. equities analysts anticipate that Innovus Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Innovus Pharmaceuticals, Inc. (INNV) Upgraded at Zacks Investment Research” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/23/innovus-pharmaceuticals-inc-innv-upgraded-at-zacks-investment-research.html.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innovus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.